Kynos Therapeutics Acquired by Dr. Falk Pharma for Novel Development

Deal News | Dec 02, 2024 | Goodwin

Kynos Therapeutics Limited, a clinical stage biopharmaceutical business hailing from a University of Edinburgh spin-out, has been acquired by Dr. Falk Pharma GmbH. Specializing in treatments for inflammatory diseases, Kynos's lead molecule KNS366 has shown significant promise in Phase I trials. The enzyme inhibitor, pivotal in addressing acute and chronic inflammatory conditions, will be integrated into Dr. Falk Pharma's pipeline, taking initial focus on acute pancreatitis. This acquisition broadens Dr. Falk's therapeutic portfolio, aligning with its historic expertise in gastrointestinal and hepatobiliary treatments. Notably, the strategic sale was facilitated by Goodwin's London Life Sciences team. Dr. Falk operates out of Freiburg, Germany, and continues its legacy as a family-owned innovator in treating intricate disorders.

Sectors

  • Biopharmaceutical
  • Healthcare

Geography

  • United Kingdom – Kynos Therapeutics is based in the UK, originating as a spin-out from the University of Edinburgh.
  • Germany – Dr. Falk Pharma is headquartered in Freiburg, Germany, and the article details their acquisition activities.

Industry

  • Biopharmaceutical – This industry is relevant as the article focuses on Kynos Therapeutics, a biopharmaceutical company developing treatments for inflammatory diseases.
  • Healthcare – Relevant due to the focus on medical treatments and therapies for chronic and acute diseases, developed by companies like Kynos and marketed by Dr. Falk.

Financials

    Participants

    NameRoleTypeDescription
    Kynos Therapeutics LimitedTarget CompanyCompanyA biopharmaceutical firm focused on novel inflammatory disease treatments, originating from Edinburgh.
    Dr. Falk Pharma GmbHBidding CompanyCompanyA German pharmaceutical company known for gastrointestinal and hepatobiliary disorder medications, acquiring Kynos.
    Epidarex CapitalInvestorCompanyA key investor in Kynos Therapeutics, specializing in transatlantic venture funding.
    IP GroupInvestorCompanyAn investor in Kynos Therapeutics supporting early-stage biotech and innovation.
    Scottish EnterpriseInvestorGovernmentScotland's national economic development agency, invested in Kynos Therapeutics.
    GoodwinLegal AdvisorCompanyProvided legal advisory services for the sale of Kynos Therapeutics, specifically their London Life Sciences team.
    Andrew HarrowLegal AdvisorPersonLead member of Goodwin's London Life Sciences team advising Kynos.
    Maria DragunLegal AdvisorPersonKey member of Goodwin's advisory team in the transaction.